Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza virus split vaccine in elderly (60+)
NCT07302256Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Quadrivalent influenza virus split vaccine (Zhifei Longcom) in influenza (3 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Unsolicited Adverse Events at 30 days, Solicited Adverse Events at 7 days and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
Quadrivalent influenza virus split vaccine (Zhifei Longcom)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07302256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302256.